Macrophage NPM1 drives anti-tumor immunity via the STAT3-CCRL2 axis.

Lei Hong, Yue Yang, Yuwen Han, Nan Ouyang, Minxuan Sun, Rongchuan Zhao

Abstract read

In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lei HongSchool of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Yue YangSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou, China.

Yuwen HanSchool of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Nan OuyangSchool of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Minxuan SunSchool of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Rongchuan ZhaoSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although nucleophosmin (NPM1) is a well-characterized oncogene in acute myeloid leukemia, much less is known about its role in solid tumor immunity. Here, we examined the function of NPM1 in regulating anti-tumor immunity within the tumor microenvironment. Methods: The proportion and functional changes of macrophages and T cells were detected by flow cytometry, the downstream regulatory genes of Results: NPM1 inhibition or genetic deficiency promoted tumor growth in MC38 colon cancer and LLC lung cancer mice models. Conclusion: Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.

Indexed as

Colonic NeoplasmsMacrophagesNucleophosminSTAT3 Transcription FactorAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansMiceMice, Inbred C57BLMice, KnockoutSignal TransductionTumor MicroenvironmentNPM1 protein, humanNpm1 protein, mouseNucleophosminStat3 protein, mouseSTAT3 Transcription FactorCCRL2NPM1stat3TAMs polarizationT celltumor immunity

Identifiers

PMID42559137

DOI10.3389/fimmu.2026.1748791

PMCPMC13439533

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.